BofA Maintains an Underperform Rating on Hims & Hers Health, Inc. (HIMS) [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
TheFly reported on January 8, 2026, that BofA reduced the price target for Hims & Hers Health, Inc. (NYSE:HIMS) to $29 from $32. It retained an Underperform rating on the stock. The firm claims that the consensus expectations for sales and EBITDA margins in 2026 are excessively high. It notes that 2026 will be Hims & Hers' “big investment year” and that projections for an increase in EBITDA margin seem excessively optimistic. BofA expects negative earnings revisions in the upcoming months and risks of downside to 2026 revenue and EBITDA margins. Citi reported on January 5, 2026, that the corporation was once more left off of Novo Nordisk's partner list for the Wegovy weight loss pill's U.S. launch. It also includes CVS Health, Costco, LifeMD, and GoodRx. This exclusion is possibly due to differences between Novo and the company's compounded semaglutide strategy. In 2026, Citi forecasts that the Wegovy launch will put pressure on Hims & Hers Health, Inc. (NYSE:HIMS) GLP-1 business.
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers And HIMZ: Short-Term Pain From Novo, Long-Term Opportunity Still Bright [Seeking Alpha]Seeking Alpha
- Hims & Hers: Growth Catalysts Or Margin Trap [Seeking Alpha]Seeking Alpha
- Why Hims & Hers Health (HIMS) Is Down 6.8% After Amazon Pharmacy Adds Wegovy Weight-Loss Pill [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health (NYSE:HIMS) is now covered by analysts at Evercore ISI. They set an "in-line" rating and a $33.00 price target on the stock.MarketBeat
- Is It Too Late To Consider Hims & Hers Health (HIMS) After Recent Share Price Pullback [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 1/7/26 - Form 4
- 12/23/25 - Form 4
- 12/22/25 - Form 144
- HIMS's page on the SEC website